U.S. Markets closed

Egalet to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on May 16, 2019

WAYNE, Penn., May 14, 2019 /PRNewswire/ -- Egalet Corporation (ZCOR) ("Egalet"), a commercial-stage life sciences company focused on marketing treatments for different types of pain and inflammation, today announced that its first quarter 2019 financial results will be released on Thursday, May 16, 2019. Following the announcement, Egalet's management will host a live conference call and webcast at 4:30 p.m. Eastern Time to review the company's financial and operating results and provide a general business update.  

Egalet Logo. (PRNewsFoto/Egalet Corporation) (PRNewsfoto/Egalet Corporation)

Interested parties may listen to the call via a live audio webcast which may be accessed by visiting Egalet's website. Please connect to the website a few minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Individuals also may participate in the call by dialing 1-888-346-2615 (domestic) or 1-412-902-4253 (international) and asking for the "Egalet Earnings Call." The replay will be available approximately two hours after the call on the Egalet website.

About Egalet
Egalet, a commercial-stage life sciences company, is focused on marketing treatments for different types of pain and inflammation. Given the need for various types of pain products and the ongoing issue of prescription opioid abuse, Egalet is focused on bringing non-narcotic products and abuse-discouraging formulations of opioids to individuals in pain and the healthcare providers who care for them. Egalet markets six products: SPRIX® (ketorolac tromethamine) Nasal Spray, ZORVOLEX® (diclofenac), VIVLODEX® (meloxicam), TIVORBEX® (indomethacin), INDOCIN® (indomethacin) suppositories, INDOCIN oral suspension capsules and OXAYDO® (oxycodone HCI, USP) tablets for oral use only —CII.

For full prescribing information, boxed warnings and medication guides, please visit the following sites for each product: sprix.com, vivlodex.com, zorvolex.com, tivorbex.com, and oxaydo.com. Prescribing information, the boxed warning and medication guide for INDOCIN oral suspension and suppositories, can be found at dailymed.nlm.nih.gov.

Safe Harbor
Statements included in this press release (including but not limited to upcoming milestones) that are not historical in nature and contain the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," "look forward to" and other similar expressions are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: our ability to continue as a going concern; the impact of our bankruptcy on our business going forward, including with regard to relationships with vendors and customers, employee attrition, and the costs and expenses resulting from our bankruptcy; the impact of our acquisition of five products from Iroko Pharmaceuticals, Inc., including our assumption of related liabilities, potential exposure to successor liability and credit risk of Iroko and its affiliates; our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our current and future indebtedness; our ability to maintain compliance with the covenants in our debt documents; the level of commercial success of our products; our ability to execute on our sales and marketing strategy, including developing relationships with customers, physicians, payors and other constituencies; the rate and degree of market acceptance of any of our products; the success of competing products that are or become available; the entry of any generic products for any of our products, or any delay in or inability to reformulate SPRIX; recently enacted and future legislation and regulations regarding the healthcare system; the accuracy of our estimates of the size and characteristics of the potential markets for our products and our ability to serve those markets; our failure to recruit or retain key personnel, including our executive officers; obtaining and maintaining intellectual property protection for our products; our ability to operate our business without infringing the intellectual property rights of others; our ability to integrate and grow any businesses or products that we may acquire; the outcome of any litigation in which we are or may be involved; general market conditions; and other risk factors set forth in Egalet's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the United States Securities and Exchange Commission (SEC) and in other filings Egalet makes with the SEC from time to time. While Egalet may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Media and Investor Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: ir@egalet.com 
Tel: 484-259-7370  

Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/egalet-to-host-conference-call-and-webcast-to-discuss-first-quarter-2019-financial-results-on-may-16-2019-300849099.html